Moderna is preparing to test Health Secretary Robert F. Kennedy Jr.'s tougher vaccine policies with a combination flu-COVID ...

An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

In April, the CDC’s influential Advisory Committee on Immunization Practices recommended expanding RSV vaccination to ...

An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination ...

Records show that a top U.S. regulator rejected the recommendations of agency experts and limited the use of Covid vaccines.

In recent weeks, Health and Human Services Secretary Robert F. Kennedy Jr. has begun to dismantle decades of vaccine safety ...

Moderna’s latest flu vaccine, based on similar mRNA technology integrated in its COVID-19 shot, displayed optimistic outcomes ...

It's a shot in the arm for Cambridge, Massachusetts-based Moderna as it faces an evolving regulatory environment for vaccines in the US under new Health and Human Services (HHS) Secretary Robert F ...

The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...

Solid phase III efficacy results for Moderna Inc.’s seasonal influenza vaccine, mRNA-1010, may lead the company to resubmit a ...